Marta Catalina Miranda-Fernández

Marta Catalina Miranda-Fernández

Auto-generated profile, based on publicly available information

Marta Catalina Miranda-Fernández

Laboratorio de Biología Molecular y Pruebas Diagnósticas de Alta Complejidad, Fundación Cardioinfantil‐Instituto de Cardiología, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
CVCamilo Andres Velandia-Piedrahita
Camilo Andres Velandia-Piedrahita
AMAdrien Morel
Adrien Morel
DFDora Fonseca
Dora Fonseca
VHVictor Manuel Huertas-Quiñones
Victor Manuel Huertas-Quiñones
DCDavid Castillo
David Castillo
RCRodrigo Cabrera
Rodrigo Cabrera
The ELN gene encodes elastin, a fundamental protein of the extracellular matrix that confers elasticity to different tissues including blood vessels. The formation of elastin fibers is a complex process involving monomer coacervation and subsequent crosslinking. Mutations in exons 1– 29 of the ELN gene have been linked to supravalvular aortic stenosis (SVAS) whereas mutations in exons 30– 33 are associated with autosomal dominant cutis laxa (ADCL). This striking segregation has led to the hypothesis that distinct molecular mechanisms underlie both diseases. SVAS is believed to arise through haploinsufficiency while ADCL is hypothesized to be caused by a dominant negative effect. Here, we describe a patient with SVAS harboring a novel splice-site mutation in the last exon of ELN. The location of this mutation is not consistent with current knowledge of SVAS, since all mutations reported in the C-terminus have been found in ADCL patients, and a thorough evaluation did not reveal significant skin involvement in this case. RT-PCR analysis of skin tissue showed that C-terminal mutations in the region can lead to the production of aberrant transcripts through intron retention and activation of cryptic splice sites and suggest that disruption of the very last exon can lead to functional haploinsufficiency potentially related to SVAS.

22 March 2018 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
RCRodrigo Cabrera
Rodrigo Cabrera
MMMarta Catalina Miranda‐Fernández
Marta Catalina Miranda‐Fernández
VHVictor Manuel Huertas‐Quiñones
Victor Manuel Huertas‐Quiñones
MCMarisol Carreño
Marisol Carreño
IPIvonne Pineda
Ivonne Pineda
RVRodolfo José Dennis Verano
Rodolfo José Dennis Verano

28 April 2018 in Molecular Syndromology
Verified
Journal Article
Open access
PDF file
MMMarta-Catalina Miranda-Fernández
Marta-Catalina Miranda-Fernández
SRSilvia Ramírez-Oyaga
Silvia Ramírez-Oyaga
CRCarlos M. Restrepo
Carlos M. Restrepo
VHVictor-Manuel Huertas-Quiñones
Victor-Manuel Huertas-Quiñones
MBMagally Barrera-Castañeda
Magally Barrera-Castañeda
RCRodrigo Cabrera
Rodrigo Cabrera
Ebstein anomaly (EA) is a rare congenital heart defect (CHD) with a poorly characterized genetic etiology. However, some EA patients carry deletions in 1p36, all of which have been reported to carry distal deletions and share loss of the PRDM16 gene, which is currently considered the most likely candidate for EA development in this region. Here, we report a patient with an 11.96-Mb proximal 1p36 deletion, without loss of PRDM16, who presented with EA and a proximal deletion phenotype. This finding suggests that PRDM16 loss is not required for the development of EA in 1p36 deletions and that the loss of an additional proximal locus in 1p36 is also likely associated with EA. Our data suggest that a distal locus containing the SKI gene and a proximal locus containing the CHD-associated genes RERE and UBE4B are the most probable etiological factors for EA in patients with 1p36 deletion syndrome.